Center-Authored Papers

Filters: Author is Stopeck, Alison T  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Vascular Cell Adhesion Molecule-1
Southwestern United States
September 2011
Gralow JR, Lipton A, Stopeck AT.  2011.  How Do We Define Efficacy in Comparing Osteoclast-Targeted Agents in Metastatic Breast Cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(26):3591-3592.
Salvage Therapy
Receptors, Vascular Endothelial Growth Factor
Public Health Sciences Division
Middle Aged
Male
Lymphoma, Non-Hodgkin
Lymphoma, Mantle-Cell
Lymphoma, Large B-Cell, Diffuse
July 2012
Humans
Female
Gralow JR, Lipton A, Stopeck AT.  2011.  How Do We Define Efficacy in Comparing Osteoclast-Targeted Agents in Metastatic Breast Cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(26):3591-3592.
Disease-Free Survival
Clinical Research Division
Gralow JR, Lipton A, Stopeck AT.  2011.  How Do We Define Efficacy in Comparing Osteoclast-Targeted Agents in Metastatic Breast Cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(26):3591-3592.
Center-Authored Paper
Gralow JR, Lipton A, Stopeck AT.  2011.  How Do We Define Efficacy in Comparing Osteoclast-Targeted Agents in Metastatic Breast Cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(26):3591-3592.
Breast Neoplasms
Gralow JR, Lipton A, Stopeck AT.  2011.  How Do We Define Efficacy in Comparing Osteoclast-Targeted Agents in Metastatic Breast Cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(26):3591-3592.
Bone Neoplasms
Gralow JR, Lipton A, Stopeck AT.  2011.  How Do We Define Efficacy in Comparing Osteoclast-Targeted Agents in Metastatic Breast Cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(26):3591-3592.
Bone Density Conservation Agents
Gralow JR, Lipton A, Stopeck AT.  2011.  How Do We Define Efficacy in Comparing Osteoclast-Targeted Agents in Metastatic Breast Cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(26):3591-3592.
Biological Markers
Antibodies, Monoclonal
Angiogenesis Inhibitors